Jump to content
RemedySpot.com

Re: Increase in hyposapadias .... associated with all SSRI

Rate this topic


Recommended Posts

Posted

http://www.medsafe.govt.nz/profs/PUArticles/SSRIPreg.htm

SSRI Use in Pregnancy - Collaborative Decision-Making is Key

Web site: May 2008Prescriber Update 2008;29(1):7-8

Medsafe Editorial Team

Recent studies suggest that SSRI antidepressant use in pregnancy may increase the risk of congenital abnormalities. There is also evidence to suggest that use of these medicines in later stages of pregnancy can lead to neonatal complications indicative of a withdrawal syndrome, and to persistent pulmonary hypertension of the newborn. As untreated depression can adversely affect maternal and foetal well-being, decisions about the treatment of depression in pregnant women may be challenging for healthcare professionals and patients. Prescribers are encouraged to discuss the potential benefits and risks of antidepressant treatment with patients who are pregnant or are contemplating pregnancy.

Prenatal exposure to SSRIs associated with increased risk of adverse pregnancy outcomesPossible increased risk of congenital malformations with first trimester exposureRisk of neonatal complications following exposure in later stages of pregnancyPatient-physician discussion about risks and benefits of antidepressant treatment during pregnancy is key References

Prenatal exposure to SSRIs associated with increased risk of adverse pregnancy outcomes

Selective Serotonin Reuptake Inhibitors (SSRIs) are licensed in New Zealand for the treatment of depression, anxiety, and obsessive-compulsive disorders. Recent evidence suggests that the use of these medicines in pregnancy may be uncommonly associated with an increased risk of adverse effects in the newborn.1-6

Possible increased risk of congenital malformations with first trimester exposure

Recent studies have raised concerns about a possible association between maternal use of SSRIs and an increased risk of congenital malformations. These include cleft palate, hypospadias, and cardiovascular abnormalities such as septal defects.1-3 Data suggest that the risk of birth defects for women with first trimester paroxetine exposure may increase from 3% to around 4% for all congenital malformations, and from 1% to around 2% for congenital cardiac abnormalities. In studies of paroxetine, the majority of abnormalities observed have been cardiovascular in nature, of which ventricular septal defects were the most common.1-3 As yet, there is insufficient evidence to ascertain whether the risk of such congenital abnormalities is lower with other antidepressants.

Whether this observed increase in risk is attributable to SSRIs or to other confounding factors requires further analysis. Nonetheless, this new research suggests there may be an association between SSRIs and congenital malformations; this appears to be strongest for paroxetine and club foot, neural tube defects and cardiovascular abnormalities.4

Risk of neonatal complications following exposure in later stages of pregnancy

Complications in the acute neonatal period have been reported in association with maternal use of paroxetine and other SSRIs in the later stages of pregnancy.5-8 In some instances, the reported symptoms have been described as neonatal withdrawal syndrome, characterised by convulsions, irritability, excessive crying, and tremor.5,9 Other reported clinical findings have included respiratory distress, cyanosis, apnoea, hyperreflexia, lethargy, somnolence, temperature instability, feeding difficulties, hypoglycaemia, and muscle tone abnormalities.8,9

In a recent case-control study, maternal use of SSRIs after the first 20 weeks of pregnancy was associated with an increase in the risk of persistent pulmonary hypertension of the newborn (PPHN).7 Further investigation of this association is warranted; however, on the basis of this study, the absolute risk of PPHN among those who use SSRIs late in pregnancy is approximately 6 to 12 per 1000 women. This compares to 1 to 2 cases of PPHN per 1000 women in the general population.7, 8

Patient-physician discussion about risks and benefits of antidepressant treatment during pregnancy is key

Decisions surrounding minimisation of risk to the foetus while limiting morbidity from untreated maternal depression may be challenging, and should be made collaboratively with the patient. Prescribers are therefore encouraged to discuss the potential benefits and risks of antidepressant treatment during pregnancy with female patients of child-bearing age. If a patient receiving SSRI antidepressant therapy is pregnant or planning to become pregnant, her history should be reviewed and options considered. The risk of foetal exposure to antidepressant medication, untreated maternal depression, and depressive relapse associated with discontinuation of maintenance treatment should be discussed. General Practitioners may wish to seek an expert opinion from a relevant specialist. Prescribers should be particularly vigilant when reviewing ultrasound images for pregnant women who are taking an SSRI, and if necessary arrange for maternal serum alpha-fetoprotein levels to be checked.9

If a decision is taken to discontinue antidepressant treatment, or switch to another antidepressant, prescribers are reminded that this should be done in accordance with the prescribing information for the medicine to avoid possible withdrawal effects. In addition, as untreated depression can adversely affect maternal and foetal well-being, patients should be closely observed for depressive relapse if antidepressant treatment is stopped.10,11

Competing interests (authors): none declared.

References

GlaxoKline Clinical Trial Register. Epidemiological Study: Updated preliminary report on bupropion and other antidepressants, including paroxetine, in pregnancy and the occurrence of cardiovascular and major congenital malformation. http://ctr.gsk.co.uk/summary/paroxetine/studylist.asp 13 December 2005.

Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17(6):701-704.

Kallen B. Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 2006;21:221-222.

Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEJM 2007;356(26):2675-2683.

Sanz E, de Las Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. The Lancet 2005;365:482-487.

Oberlander T, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry 2006;63:898-906.

Chambers C, - S, Van Marter L, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine 2006;354(6):579-587.

GlaxoKline NZ Limited Aropax (paroxetine) data sheet 2 June 2006. www.medsafe.govt.nz/profs/Datasheet/a/Aropaxtab.htm.

LE, Adzick NS, Melchionne J, et al. Spina bifida. Lancet 2004;364(9448):1885-95.

Nonacs R, Cohen L. Assessment and treatment of depression during pregnancy: an update. Psychiatric Clinics of North America 2003;26(3):547-562.

Cohen L, Altshuler L, Harlow B, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295(5):499-507.

> > >> > >> > >> > > December 29th, 2010 by BOB FIDDAMAN> > > <http://ehealthforum.com/blogs/fiddy> [Pro]> > >> > > > > http://ehealthforum.com/blogs/fiddy/paxil-malformations-who-is-responsib\> > > le-b14405.html> > > > > <http://ehealthforum.com/blogs/fiddy/paxil-malformations-who-is-responsi\> > > ble-b14405.html>> > >> > >> > > > > <http://ehealthforum.com/health/jump_confirm.php?url=http://feedads.g.do\> > > ubleclick.net/~a/l4NGlcOLRPypQQff2L9fMA-CVjE/1/da>> > >> > > > > <http://ehealthforum.com/health/jump_confirm.php?url=http://3.bp.blogspo\> > > t.com/_4fq4nxa7Tqs/TRsZXEtthMI/AAAAAAAACIg/wEPvRIKU99o/s1600/MHRA.jpg>> > >> > >> > > A study from earlier this year by M. Reis and B. Klln showed that> > > paroxetine [brand names, Seroxat, Paxil and Aropax] seems to be> > > associated with a specific teratogenic property.> > >> > > The study was carried out because of concerns about possible adverse> > > effects of the use of antidepressant medication during pregnancy,> > > including risk for neonatal pathology and the presence of congenital> > > malformations.> > >> > > This particular study, entitled, "Delivery outcome after maternal use of> > > antidepressant drugs in pregnancy: an update using Swedish data", was> > > published in the Cambridge University Press early 2010.> > >> > > Data from the Swedish Medical Birth Register (MBR) from 1 July 1995 up> > > to 2007 were used to identify women who reported the use of> > > antidepressants in early pregnancy or were prescribed antidepressants> > > during pregnancy by antenatal care: a total of 14,821 women with 15,017> > > infants.> > >> > > The conclusion?> > >> > >> > > "Women using antidepressants during pregnancy and their newborns have> > > increased pathology. It is not clear how much of this is due to drug > > ! use> > > or underlying pathology. Use of TCAs was found to carry a higher risk> > > than other antidepressants and paroxetine seems to be associated with a> > > specific teratogenic property."> > >> > > Not so much of a conclusion really as it can be argued that is not clear> > > how much of this is due to drug use or underlying pathology - this is> > > the basis of arguments used in court rooms or 'negotiating tables' with> > > GlaxoKline's lawyers across the US.> > >> > > The majority of Paxil birth defect cases have been settled out of court,> > > the odd one or two have been lost by the claimants on legal> > > technicalities.> > >> > > The Reis/Klln study is quite significant in as much that it fingers> > > GSK's Paxil as not only being associated with a specific teratogenic> > > property, it also shows that pregnant patients taking Paxil increase the> > > chances of their babies being born with cardiovascular defects and> > > hypospadias.> > >> > > What is hypospadias?> > >> > > Hypospadias is a congenital (present at birth) problem affecting a boys> > > penis. It is a combination of three separate problems: the hole through> > > which urine passes (meatus) is not at the tip of the penis, the foreskin> > > is gathered at the back of the penis with none at the front and the> > > penis may be bent when stiff. The position of the meatus varies; in some> > > boys, the hole is only a small distance away from the tip of the penis,> > > whereas in others, it is at the base of the penis, in the scrotum or> > > behind the scrotum. [1]> > >> > > According to the Great Ormond Street Hospital for Children NHS Trust> > > website, about one in every 300 boys has hypospadias, although this> > > figure seems to be rising. It is not known why this figure is rising. So> > > we have that grey area of whether or not paroxetine increases the> > > chances of a male child being born with hypospadias. The Reis/Klln > > s! tudy> > > seems to suggest that it does.> > >> > > Who is responsible?> > >> > > So, the question, who is responsible falls into the pot. Do we point the> > > finger of blame at the manufacturer of Paxil, GlaxoKline or do we> > > scrutinise the body who regulate and license drugs in the UK, namely,> > > the MHRA?> > >> > > Even if blame is placed upon either of these two, who, or more> > > importantly, whom is responsible? What individual should take the blame> > > for allowing a known teratogen to be prescribed to pregnant patients?> > >> > > Surely, whomever it is, should be in a position to answer questions from> > > concerned members of the public, moreover, consumers of a product.> > >> > > The CEO of GlaxoKline is Witty. Should Witty go public and> > > offer an explanation as to why a drug manufactured by the company that> > > he heads could increase the chances of heart and hypospadias> > > malformations? It's one thing adding a warning to the ever increasing> > > [in text] patient information leaflet [PIL] - but is this really enough?> > > In any event, would this really be advisable considering GlaxoKline> > > are settling and defending many hundreds of Paxil birth defect trials in> > > America?> > >> > > Or do we expect more from the MHRA's CEO, Kent Woods?> > >> > > The MHRA's role is to protect the public from unsafe drugs. With> > > paroxetine top of their adverse reactions list, they could argue that> > > they are doing enough.> > >> > > The MHRA, like Glaxo, have half heartedly warned people of the risks of> > > taking paroxetine whilst pregnant. What they haven't done is label it a> > > teratogen. One would have thought that lessons were learned for the most> > > infamous teratogen of them all, Thalidomide, a drug that was mainly> > > prescribed to pregnant women for morning sickness in the late 50s and> > > early 60s. Instead the drug caused severe deformit! ies in babies with> > > missing limbs.> > >> > > Are we on the brink of Dj Vu here?> > >> > > There is a fine line of protecting patients with regard to paroxetine> > > use. The MHRA tout the risk/benefit ratio and they, apparently, would> > > not want to alarm the public over paroxetine's propensity to cause> > > malformations because they are [still] of the opinion that the benefits> > > of taking paroxetine outweigh the risks.> > >> > > The Reis/Klln study would suggest otherwise.> > >> > > Wise up - pull the drug.> > >> > > The study is available for download [for a fee] HERE> > > > > <http://ehealthforum.com/health/jump_confirm.php?url=http://journals.cam\> > > bridge.org/action/displayAbstract?fromPage%3Donline%26aid%3D7878627>> > >> > >> >> >> >> >>

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...